Published Online First

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Creative Commons).

B. A. C. Dijkmans
L. A. Aarden

September 2016

Type article Title Relationship between serum trough infliximab levels, pretreatment C reactive prot...

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

Wijbrandts, C. A.
Dijkgraaf, M. G. W.
Kraan, M. C.
Vinkenoog, M.
Smeets, T. J.
Dinant, H.
Vos, K.
Lems, W. F.
Wolbink, G. J.
Sijpkens, D.
Dijkmans, B. A. C.
Tak, P. P.

January 2008

Objective: To determine whether the heterogeneous clinical response to tumour necrosis factor (TNF)a...

Published Online First

B A C Dijkmans
L Aarden

January 2004

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and cli...

Published Online First

B A C Dijkmans
L Aarden

January 2004

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and cli...

Published Online First

Inserm U
Et Recherche Clinique
Pr Xavier Mariette
Service De

January 2007

A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthri...

Published Online First

Hospital Clı́nic De Barcelona
Investigación Servicio De
J D Cañete

January 2008

Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis fa...

Regulation of interferon response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

van Baarsen, L.G.M.
Wijbrandts, C.A.
Rustenburg, F.
Cantaert, T.
van der Pouw Kraan, T.C.T.M.
Baeten, D.L.
Dijkmans, B.A.C.
Tak, P.P.
Verweij, C.L.

January 2010

ABSTRACT: INTRODUCTION: Cross-regulation between tumor necrosis factor (TNF) and type I interferon (...

Published Online First

Herne German
Berlin Charite ́ Hospital

January 2007

Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in ...

How does infliximab work in rheumatoid arthritis?

Maini, RN
Feldmann, M

January 2002

Since the initial characterization of tumor necrosis factor alpha (TNFalpha), it has become clear th...

RESEARCH ARTICLE Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients

Kenzie D. Macisaac
Richard Baumgartner
Jia Kang
Andrey Loboda
Charles Peterfy
Julie Dicarlo
Jonathan Riek
Chan Beals

August 2016

Approximately 30 % of rheumatoid arthritis patients achieve inadequate response to anti-TNF biologic...

Published Online First

Elisabeth Hjardem
Mikkel Østergaard
Jan Pødenphant
Ulrik Tarp
Lis Smedegaard Andersen
Elisabeth Peen
Hanne Merete Lindegaard
Vibeke Stevenius Ringsdal
Anne Rødgaard
Annette Hansen
Hans Henrik Mogensen
Janne Unkerskov
Merete Lund Hetl
Hospital At Hvidovre

January 2007

rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a secon...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Creative Commons).

B. A. C. Dijkmans
L. A. Aarden

September 2016

Type article Title Relationship between serum trough infliximab levels, pretreatment C reactive prot...

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

Wijbrandts, C. A.
Dijkgraaf, M. G. W.
Kraan, M. C.
Vinkenoog, M.
Smeets, T. J.
Dinant, H.
Vos, K.
Lems, W. F.
Wolbink, G. J.
Sijpkens, D.
Dijkmans, B. A. C.
Tak, P. P.

January 2008

Objective: To determine whether the heterogeneous clinical response to tumour necrosis factor (TNF)a...

Published Online First

B A C Dijkmans
L Aarden

January 2004

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and cli...

Published Online First

B A C Dijkmans
L Aarden

January 2004

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and cli...

Published Online First

Inserm U
Et Recherche Clinique
Pr Xavier Mariette
Service De

January 2007

A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthri...

Published Online First

Hospital Clı́nic De Barcelona
Investigación Servicio De
J D Cañete

January 2008

Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis fa...

Regulation of interferon response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

van Baarsen, L.G.M.
Wijbrandts, C.A.
Rustenburg, F.
Cantaert, T.
van der Pouw Kraan, T.C.T.M.
Baeten, D.L.
Dijkmans, B.A.C.
Tak, P.P.
Verweij, C.L.

January 2010

ABSTRACT: INTRODUCTION: Cross-regulation between tumor necrosis factor (TNF) and type I interferon (...

Published Online First

Herne German
Berlin Charite ́ Hospital

January 2007

Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in ...

How does infliximab work in rheumatoid arthritis?

Maini, RN
Feldmann, M

January 2002

Since the initial characterization of tumor necrosis factor alpha (TNFalpha), it has become clear th...

RESEARCH ARTICLE Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients

Kenzie D. Macisaac
Richard Baumgartner
Jia Kang
Andrey Loboda
Charles Peterfy
Julie Dicarlo
Jonathan Riek
Chan Beals

August 2016

Approximately 30 % of rheumatoid arthritis patients achieve inadequate response to anti-TNF biologic...

Published Online First

Elisabeth Hjardem
Mikkel Østergaard
Jan Pødenphant
Ulrik Tarp
Lis Smedegaard Andersen
Elisabeth Peen
Hanne Merete Lindegaard
Vibeke Stevenius Ringsdal
Anne Rødgaard
Annette Hansen
Hans Henrik Mogensen
Janne Unkerskov
Merete Lund Hetl
Hospital At Hvidovre

January 2007

rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a secon...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan
Maini, R. N.

April 2001

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosi...

Creative Commons).

B. A. C. Dijkmans
L. A. Aarden

September 2016

Type article Title Relationship between serum trough infliximab levels, pretreatment C reactive prot...

Published Online First

Abstract

Extracted data

Published Online First

Abstract

Extracted data

Related items

Related items